Faron Pharmaceuticals Oy (LON:FARN) Sets New 1-Year Low – Should You Sell?

Faron Pharmaceuticals Oy (LON:FARN)’s share price reached a new 52-week low on Tuesday . The stock traded as low as GBX 48 and last traded at GBX 48.75, with a volume of 357475 shares changing hands. The stock had previously closed at GBX 53.50.

Faron Pharmaceuticals Oy Stock Up 1.1%

The firm’s 50 day simple moving average is GBX 155.47 and its 200-day simple moving average is GBX 179.86. The company has a current ratio of 1.45, a quick ratio of 1.09 and a debt-to-equity ratio of 922.55. The stock has a market capitalization of £53.78 million, a price-to-earnings ratio of -1.74 and a beta of 0.36.

Insider Transactions at Faron Pharmaceuticals Oy

In related news, insider Jurriaan Dekkers sold 4,000 shares of Faron Pharmaceuticals Oy stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of GBX 182, for a total transaction of £7,280. 4.05% of the stock is owned by company insiders.

Faron Pharmaceuticals Oy Company Profile

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.